MRS. MARION E COLE MD
Prescription History 1255642849
Internal Medicine - Medical Oncology in Fairfax, VA


Quality Rating: 81.28 out of 100 score

NPI Status: Active since June 29, 2010

Contact Information

8081 INNOVATION PARK DR
FAIRFAX, VA
ZIP 22031
Phone: (571) 472-4724
Fax: (571) 472-0241

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MRS. MARION E COLE MD, an active Medical Oncology specialist practicing in Fairfax, VA. Our medical registry currently tracks 27 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 784 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 93 claims alone.


Acyclovir

Generic Formulation: AcyclovirSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 61
30-Day Fills 86.0
Days Supply 2,407
VA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills36.7
Peer Average Days Supply993
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 177.3% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,552.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.46

State Avg Cost Per Claim

$26.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Alecensa

Generic Formulation: Alectinib HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
VA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.7
Peer Average Days Supply500
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $240,099.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,469.18

State Avg Cost Per Claim

$18,432.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Alectinib is used to treat a certain type of lung cancer. It works by slowing or stopping the growth of cancer cells. Alectinib belongs to a class of drugs known as tyrosine kinase inhibitors.

Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 44.0
Days Supply 1,316
VA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills86.6
Peer Average Days Supply2,576
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.1% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $82.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.83

State Avg Cost Per Claim

$11.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 25
30-Day Fills 57.5
Days Supply 1,725
VA State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills148.3
Peer Average Days Supply4,433
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.0% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,486.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$59.48

State Avg Cost Per Claim

$28.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Brukinsa

Generic Formulation: ZanubrutinibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 660
VA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.5
Peer Average Days Supply585
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $331,669.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,075.87

State Avg Cost Per Claim

$13,385.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
VA State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.0
Peer Average Days Supply390
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $95,441.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,676.52

State Avg Cost Per Claim

$15,072.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 50
30-Day Fills 60.4
Days Supply 1,460
VA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply510
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 66.7% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,166.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.33

State Avg Cost Per Claim

$18.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 93
30-Day Fills 137.0
Days Supply 4,068
VA State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills118.3
Peer Average Days Supply3,347
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 27.4% more claims than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $80,683.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$867.57

State Avg Cost Per Claim

$843.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Enoxaparin Sodium

Generic Formulation: Enoxaparin SodiumSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 48.0
Days Supply 1,205
VA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.1
Peer Average Days Supply283
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 89.5% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,016.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$417.12

State Avg Cost Per Claim

$209.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enoxaparin is used to prevent and treat harmful blood clots. This helps to reduce the risk of a stroke or heart attack. This medication helps keep your blood flowing smoothly by lowering the activity of clotting proteins in the blood. Enoxaparin is an anticoagulant, also known as a blood thinner. It is a type of heparin. Conditions which increase your risk of developing blood clots include certain types of surgeries (such as knee/hip replacement, abdominal), long periods of being immobile, certain types of heart attack, and a specific type of chest pain called unstable angina. For some medical conditions, enoxaparin may be used in combination with other blood thinners.

Gabapentin

Generic Formulation: GabapentinSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 43
30-Day Fills 59.0
Days Supply 1,610
VA State Average Benchmarks
Peer Average Claims89.0
Peer Average 30-Day Fills132.3
Peer Average Days Supply3,808
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.7% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $442.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.30

State Avg Cost Per Claim

$19.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 89
30-Day Fills 161.6
Days Supply 4,825
VA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills59.2
Peer Average Days Supply1,751
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 196.7% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,692.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.25

State Avg Cost Per Claim

$38.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
VA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply599
Conservative Utilization

This provider writes prescriptions for this formulation 42.1% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $54,678.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,970.77

State Avg Cost Per Claim

$2,345.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
VA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.6
Peer Average Days Supply584
Conservative Utilization

This provider writes prescriptions for this formulation 31.6% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $225,066.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,312.78

State Avg Cost Per Claim

$16,219.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 53
30-Day Fills 53.0
Days Supply 1,372
VA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.7
Peer Average Days Supply490
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 194.4% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $666,617.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,577.69

State Avg Cost Per Claim

$14,126.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Letrozole

Generic Formulation: LetrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 47
30-Day Fills 138.0
Days Supply 4,140
VA State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills137.4
Peer Average Days Supply4,107
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,879.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.99

State Avg Cost Per Claim

$37.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Levofloxacin

Generic Formulation: LevofloxacinSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 125
VA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.7
Peer Average Days Supply199
Conservative Utilization

This provider writes prescriptions for this formulation 47.8% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.76

State Avg Cost Per Claim

$9.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The L-isomer of Ofloxacin.

Therapeutic Applications

This medication is used to treat a variety of bacterial infections. Levofloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. Levofloxacin injection is used if you cannot take the medication by mouth. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Mirtazapine

Generic Formulation: MirtazapineSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
VA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills62.3
Peer Average Days Supply1,810
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.7% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $134.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.22

State Avg Cost Per Claim

$24.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Therapeutic Applications

Mirtazapine is used to treat depression. It improves mood and feelings of well-being. Mirtazapine is an antidepressant that works by restoring the balance of natural chemicals (neurotransmitters) in the brain.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 224
VA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.1
Peer Average Days Supply293
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $668.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.17

State Avg Cost Per Claim

$22.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 123
VA State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills56.4
Peer Average Days Supply1,123
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.4% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $167.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.46

State Avg Cost Per Claim

$25.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Pomalyst

Generic Formulation: PomalidomideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 560
VA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.4
Peer Average Days Supply786
Conservative Utilization

This provider writes prescriptions for this formulation 28.6% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $449,583.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$22,479.20

State Avg Cost Per Claim

$20,760.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). It works by slowing or stopping the growth of cancer cells.

Prednisone

Generic Formulation: PrednisoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 30.3
Days Supply 894
VA State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills56.5
Peer Average Days Supply1,001
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.1% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $230.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.39

State Avg Cost Per Claim

$6.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 144
VA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply345
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.9% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $131.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.10

State Avg Cost Per Claim

$17.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Revlimid

Generic Formulation: LenalidomideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 959
VA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills40.4
Peer Average Days Supply1,081
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $571,784.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,336.69

State Avg Cost Per Claim

$18,069.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 39.8
Days Supply 1,164
VA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.4
Peer Average Days Supply347
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $325.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.11

State Avg Cost Per Claim

$5.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Tagrisso

Generic Formulation: Osimertinib MesylateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
VA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.2
Peer Average Days Supply573
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $182,076.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,173.04

State Avg Cost Per Claim

$16,804.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
VA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply652
Conservative Utilization

This provider writes prescriptions for this formulation 42.1% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $828.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$75.35

State Avg Cost Per Claim

$51.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 40.0
Days Supply 1,200
VA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills64.4
Peer Average Days Supply1,847
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,813.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,300.82

State Avg Cost Per Claim

$925.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MRS. MARION E COLE MD provides transparency into local medical care patterns within Fairfax, VA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.